BioSpace News Archive

DUR-928 is an endogenous, first-in-class small molecule, which may have broad applicability in several hepatic and renal diseases such as nonalcoholic steatohepatitis (NASH) and other disorders of the liver such as PSC, in acute organ injuries such as acute liver and kidney injury, and in inflammatory skin disorders such as psoriasis and atopic dermatitis.

New system will include smartphone-enabled sales and distribution system connecting medicinal cannabis patients with local dispensary drivers for fast delivery and monitoring of orders.

Financing to Further Support Growth of MRIdian Linac

- New analysis from COMPASS examines the use of XARELTO® plus aspirin in reducing major adverse limb events in patients with peripheral artery disease - New CANVAS Program data assess the impact of INVOKANA® on heart failure in patients with T2D with an elevated risk of cardiovascular disease - Janssen leads in cardiovascular innovation using real-world data from wearable electrocardiogram sensors to detect asymptomatic atrial fibrillation

Five presentations of clinical and preclinical data from Magenta programs –Two presentations named among best in conference.

Belong Machine-Learning Provides Tailored Digital Education and Support to Patients Navigating the Cancer Treatment Journey

McKesson Specialty Health, a division of McKesson Corporation, announced a strategic collaboration with Cryoport, Inc. (NASDAQ: CYRX, CYRXW) designed to further strengthen its robust logistics services to support the delivery of cell and gene therapies to patients at the point of care.

Jeffrey Chodakewitz, M.D., to retire and serve as senior advisor through early 2019. Dr. Kewalramani to become CMO and Executive Vice President, Global Medicines Development and Medical Affairs, on April 1, 2018.

Study in The Journal of the American Osteopathic Association Suggests Up to 50 Percent of U.S. Population is Magnesium Deficient

Two-day conference draws cardiac electrophysiology experts from across the globe